Advertisement
PAPERS| Volume 151, SUPPLEMENT 1, S43-S47, March 2017

Antiphospholipid syndrome

DOI:https://doi.org/10.1016/S0049-3848(17)30066-X
Antiphospholipid syndrome
Previous ArticleAnticoagulants to prevent recurrent placenta-mediated pregnancy complications: Is it time to put the needles away?
Next ArticleImpact of haemostatic mechanisms on pathophysiology of preeclampsia
      This paper is only available as a PDF. To read, Please Download here.

      ABSTRACT

      The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40–50 cases per 100,000 persons. The aPL are positive in approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients with deep vein thrombosis and 6% of patients with pregnancy morbidity.
      Currently, there is consensus in treating APS patients with thrombosis with long-term oral anticoagulation and to prevent obstetric manifestations with the use of aspirin and heparin. This review summarizes the main knowledge on the clinical and therapeutic aspects of this syndrome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Cervera R.
        • Espinosa
        • Khamashta M.A.
        Antiphospholipid syndrome in systemic autoimmune diseases. 2nd edition. Elsevier, Amsterdam2016
        • Cervera R.
        • Asherson R.A.
        • Acevedo M.L.
        • Gomez-Puerta J.A.
        • Espinosa G.
        • De La Red G.
        • et al.
        Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.
        Ann Rheum Dis. 2004; 63: 1312-1317
        • Gómez-Puerta J.A.
        • Cervera R.
        • Espinosa G.
        • Aguiló S.
        • Bucciarelli S.
        • Ramos-Casals M.
        • et al.
        Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.
        Semin Arthritis Rheum. 2006; 35: 322-332
        • Gómez-Puerta J.A.
        • Martin H.
        • Amigo M.C.
        • Aguirre M.A.
        • Camps M.T.
        • Cuadrado M.J.
        • et al.
        Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?.
        Medicine (Baltimore). 2005; 84: 225-230
        • Rodriguez-Pintó I.
        • Moitinho M.
        • Santacreu I.
        • Shoenfeld Y.
        • Erkan D.
        • Espinosa G.
        • et al.
        Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry.
        Autoimmun Rev. 2016; 15: 1120-1124
        • Durcan L.
        • Petri M.
        Epidemiology of the Antiphospholipid Syndrome.
        in: Cervera R. Espinosa Khamashta M.A. 2nd edition. Antiphospholipid syndrome in systemic autoimmune diseases. Elsevier, Amsterdam2016: 17-30
        • Andreoli L.
        • Chighizola C.B.
        • Banzato A.
        • Pons-Estel G.J.
        • Ramire de Jesus G.
        • Erkan D.
        Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.
        Arthritis Care Res (Hoboken). 2013; 65: 1869-1873
        • Cervera R.
        • Espinosa G.
        • Bucciarelli S.
        • Gomez-Puerta J.A.
        • Font J.
        Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry.
        Autoimmun Rev. 2006; 6: 81-84
        • Cervera R.
        • Bucciarelli S.
        • Plasin M.A.
        • Gomez-Puerta J.A.
        • Plaza J.
        • Pons-Estel G.
        • et al.
        Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".
        J Autoimmun. 2009; 32: 240-245
        • Espinosa G.
        • Cervera R.
        Antiphospholipid syndrome: frequency, main causes and risk factors of mortality.
        Nat Rev Rheumatol. 2010; 6: 296-300
        • Giannakopoulos B.
        • Krilis S.A.
        The pathogenesis of the antiphospholipid syndrome.
        N EnglJ Med. 2013; 368: 1033-1044
        • Cervera R.
        • Piette J.C.
        • Font J.
        • Khamashta M.A.
        • Shoenfeld Y.
        • Camps M.T.
        • et al.
        Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
        Arthritis Rheum. 2002; 46: 1019-1027
        • Cervera R.
        • Khamashta M.A.
        • Shoenfeld Y.
        • Camps M.T.
        • Jacobsen S.
        • Kiss E.
        • et al.
        Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.
        Ann Rheum Dis. 2009; 68: 1428-1432
        • Cervera R.
        • Serrano R.
        • Pons-Estel G.J.
        • Ceberio-Hualde L.
        • Shoenfeld Y.
        • de Ramón E.
        • et al.
        Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
        Ann Rheum Dis. 2015; 74: 1011-1018
        • Ruffatti A.
        • Calligaro A.
        • Hoxha A.
        • Trevisanuto D.
        • Ruffatti A.T.
        • Gervasi M.T.
        • et al.
        Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome.
        Arthritis Care Res (Hoboken). 2010; 62: 302-307
        • Sciascia S.
        • Sanna G.
        • Murru V.
        • Roccatello D.
        • Khamashta M.A.
        • Bertolaccini M.L.
        GAPSS: the Global Anti-Phospholipid Syndrome Score.
        Rheumatology (Oxford). 2013; 52: 1397-1403
        • Wilson W.A.
        • Gharavi A.E.
        • Koike T.
        • Lockshin M.D.
        • Branch D.W.
        • Piette J.C.
        • et al.
        International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.
        Arthritis Rheum. 1999; 42: 1309-1311
        • Miyakis S.
        • Lockshin M.D.
        • Atsumi T.
        • Branch D.W.
        • Brey R.L.
        • Cervera R.
        • et al.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J Thromb Haemost. 2006; 4: 295-306
        • Kaul M.
        • Erkan D.
        • Sammaritano L.
        • Lockshin M.D.
        Assessment of the 2006 revised antiphospholipid syndrome classification criteria.
        Ann Rheum Dis. 2007; 66: 927-930
        • Asherson R.A.
        • Cervera R.
        • de Groot P.G.
        • Erkan D.
        • Boffa M.C.
        • Piette J.C.
        • et al.
        Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines.
        Lupus. 2003; 12: 530-534
        • Cervera R.
        • Font J.
        • Gomez-Puerta J.A.
        • Espinosa G.
        • Cucho M.
        • Bucciarelli S.
        • et al.
        Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.
        Ann Rheum Dis. 2005; 64: 1205-1209
        • Ruiz-Irastorza G.
        • Cuadrado M.J.
        • Ruiz-Arruza I.
        • Brey R.
        • Crowther M.
        • Derksen R.
        • et al.
        Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.
        Lupus. 2011; 20: 206-218
        • Andrade D.
        • Cervera R.
        • Cohen H.
        • Crowther M.
        • Cuadrado M.
        • Canaud G.
        • et al.
        Erkan D. Lockshin M. 15th International Congress on Antiphospholipid Antibodies - Task Force on Antiphospholipid Syndrome Treatment Trends Report APS Current Research Highlights and Clinical Insights, Springer2017 (in press)
        • Erkan D.
        • Vega J.
        • Ramon G.
        • Kozora E.
        • Lockshin M.D.
        A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.
        Arthritis Rheum. 2013; 65: 464-771
        • Berman H.
        • Rodriguez-Pinto I.
        • Cervera R.
        • Morel N.
        • Costedoat-Chalumeau N.
        • Erkan D.
        • et al.
        Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab.
        Autoimmun Rev. 2013; 12: 1085-1090
        • Shapira I.
        • Andrade D.
        • Allen S.L.
        • Salmon J.E.
        Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.
        Arthritis Rheum. 2012; 64: 2719-2723
        • Erkan D.
        • Harrison M.J.
        • Levy R.
        • Peterson M.
        • Petri M.
        • Sammaritano L.
        • et al.
        Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphos-pholipid antibody-positive individuals.
        Arthritis Rheum. 2007; 56: 2382-2391
        • Espinosa G.
        • Cervera R.
        Current treatment of antiphospholipid syndrome: lights and shadows.
        Nat Rev Rheumatol. 2015; 11: 586-596
        • Gómez-Puerta J.A.
        • Cervera R.
        Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?.
        Lupus. 2013; 22: 754-755
        • Grika E.P.
        • Ziakas P.D.
        • Zintzaras E.
        • Moutsopoulos H.M.
        • Vlachoyiannopoulos P.G.
        Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome.
        J Rheumatol. 2012; 39: 516-523

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0049-3848(17)30066-X

      Copyright

      © 2017 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX